Publications & Posters

Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial

Multiple Sclerosis Journal | January 12, 2023

Jens Kuhle, Tanuja Chitnis, Brenda Banwell, Marc Tardieu, Douglas L Arnold, Andreea M Rawlings, Svend S Geertsen, Alex L Lublin, Stephane Saubadu, Philippe Truffinet, Ludwig Kappos

Multiple Sclerosis Journal. 2023;0(0).



The phase 3 TERIKIDS study demonstrated efficacy and manageable safety for teriflunomide versus placebo in children with relapsing multiple sclerosis (RMS).


Evaluate plasma neurofilament light chain (pNfL) concentrations in TERIKIDS.


Patients received placebo or teriflunomide (14 mg adult equivalent) for up to 96 weeks in the double-blind (DB) period. In the open-label extension (OLE), all patients received teriflunomide until up to 192 weeks after randomization. pNfL was measured using single-molecule array assay (Simoa® NF-light).


Baseline mean age was 14.5 years; 69.4% were female. Baseline geometric least square mean pNfL levels were similar for teriflunomide (n = 78) and placebo (n = 33) patients (19.83 vs 18.30 pg/mL). Over the combined DB and OLE periods, pNfL values were lower for teriflunomide versus placebo (analysis of variance p < 0.01; Week 192: 10.61 vs 17.32 pg/mL). Observed between-group pNfL differences were attenuated upon adjustment for gadolinium (Gd)-enhancing or new/enlarged T2 lesion counts at DB Week 24. Higher baseline pNfL levels were associated with shorter time since first MS symptom onset, higher baseline Gd-enhancing lesion counts and T2 lesion volume, and increased hazard of high magnetic resonance imaging activity or clinical relapse during the DB period.


Teriflunomide treatment was associated with significantly reduced pNfL levels in children with RMS.